rabusertib
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00415636)
Timeline
Indications
Mechanism of action
- Serine/threonine-protein kinase Chk1INHIBITOR
CHEK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1- Mol. weight
- 436.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3039517 ↗
Also known as
- ic-83
- ic-83
- ly2603618
- ly2603618
- ly-2603618
- ly-2603618
- rabusertib
- rabusertib
- rabusertib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01358968 | Phase 1 | Jun 1, 2011 | Eli Lilly |
| NCT01341457 | Phase 1 | May 1, 2011 | Eli Lilly |
| NCT01139775 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2011 | Eli Lilly |
| NCT01296568 | Phase 1 | Feb 1, 2011 | Eli Lilly |
| NCT00988858 | Phase 2 | Nov 1, 2009 | Eli Lilly |
| NCT00839332 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2009 | Eli Lilly |
| NCT00415636 | Phase 1 | Dec 1, 2006 | Eli Lilly |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 7 | 7 | 2 | 2006 |
1 organizations
Page 1 / 1